Recent Quotes (30 days)

You have no recent quotes
chg | %

NanoVibronix Inc  

(Public, NASDAQ:NAOV)   Watch this stock  
Find more results for NAOV
-0.41 (-8.40%)
Jan. 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.47 - 4.90
52 week 3.68 - 7.32
Open 4.86
Vol / Avg. 9,339.00/16,388.00
Mkt cap 16.87M
P/E     -
Div/yield     -
EPS -1.15
Shares 3.77M
Beta     -
Inst. own 10%

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin -2460.00% -1236.24%
Operating margin -943.08% -1011.35%
EBITD margin - -1008.30%
Return on average assets -819.10% -228.58%
Return on average equity - -
Employees 8 -
CDP Score - -


9 Derech Hashalom Street
NESHER, NY 36651
+1-631-5744410 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NanoVibronix, Inc. is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy. The Company's products include PainShield, WoundShield and UroShield. Its products under development include Renooskin and Endotrachshield. The Company's principal research and development activities are conducted in Israel, through its subsidiary, NanoVibronix (Israel 2003) Ltd. The Company operates in the United States, Europe and India, among others. The PainShield is a disposable patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. The Company's WoundShield system is a patch-based therapeutic ultrasound device that facilitates tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.

Officers and directors

Christopher M. Fashek Chairman of the Board
Bio & Compensation  - Reuters
William Stern Ph.D. President
Age: 72
Bio & Compensation  - Reuters
Brian M. Murphy Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Stephen Russell Brown Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Jona Zumeris Ph.D. Vice President - Technology , Director
Age: 63
Bio & Compensation  - Reuters
Harold Jacob M.D. Chief Medical Officer, Director
Age: 60
Bio & Compensation  - Reuters
Martin S. Goldstein MD Director
Age: 46
Bio & Compensation  - Reuters
Michael Ferguson Independent Director
Age: 43
Bio & Compensation  - Reuters
Thomas R. Mika Independent Director
Age: 64
Bio & Compensation  - Reuters